AJR InPractice
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costouros, N. G.
Right arrow Articles by Kurhanewicz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costouros, N. G.
Right arrow Articles by Kurhanewicz, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
DOI:10.2214/AJR.06.0165
AJR 2007; 188:812-816
© American Roentgen Ray Society


Original Research

Diagnosis of Prostate Cancer in Patients with an Elevated Prostate-Specific Antigen Level: Role of Endorectal MRI and MR Spectroscopic Imaging

Nick G. Costouros1, Fergus V. Coakley, Antonio C. Westphalen, Aliya Qayyum, Benjamin M. Yeh, Bonnie N. Joe and John Kurhanewicz

1 All authors: Department of Radiology, University of California, San Francisco, 505 Parnassus Ave., Rm. M-372, Box 0628, San Francisco, CA 94143-0628.

OBJECTIVE. The objective of our study was to determine the accuracy of endorectal MRI and MR spectroscopic imaging (MRSI) in the diagnosis of prostate cancer in patients with an elevated serum prostate-specific antigen (PSA) level.

MATERIALS AND METHODS. We retrospectively identified 40 patients with an elevated serum PSA level and without a histologic diagnosis of prostate cancer who underwent endorectal MRI and MRSI at our institution. On the basis of MRI findings alone and then combined MRI and MRSI findings, a single experienced observer rated the presence or absence of prostate cancer in each side of the prostate on a 5-point scale (1 = definitely absent, 5 = definitely present). Areas under the receiver operating characteristic (ROC) curve were calculated using the hemiprostate as the unit of analysis. The presence or absence of cancer on subsequent endorectal sonographically guided sextant biopsy was used as the standard of reference.

RESULTS. Biopsy revealed no cancer in 24 patients, bilateral cancer in 11, and unilateral cancer in five. The areas under the ROC curve for the diagnosis of prostate cancer by hemigland was 0.70 for MRI alone and 0.63 for combined MRI and MRSI (no significant difference, p =0.32).

CONCLUSION. Endorectal MRI and MRSI are reasonably accurate for the diagnosis of prostate cancer in patients with an elevated serum PSA level, but the remaining limitations suggest that MRI and MRSI should be used as a supplement rather than a replacement for biopsy using the current technology and diagnostic criteria.

Keywords: MRI • MR spectroscopic imaging • oncologic imaging • prostate • prostate cancer


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
V. Kundra, P. M. Silverman, S. F. Matin, and H. Choi
Imaging in Oncology from The University of Texas M. D. Anderson Cancer Center: Diagnosis, Staging, and Surveillance of Prostate Cancer
Am. J. Roentgenol., October 1, 2007; 189(4): 830 - 844.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Roentgen Ray Society.